Unidad de Oncología Traslacional
Hospital Universitario Fundación Jiménez Díaz
DESCRIPTION OF THE OFFER
Polo-like kinase 1 (PLK1) is an essential protein in communicating cell-cycle progression. Its overexpression has been validated as a marker for poor prognosis in many cancers including colorectal cancer. PLK1 knockdown decreases the survival of cancer cells, therefore different PLK1 inhibitors are currently under clinical investigation. However, the observed efficacy of these inhibitors is not as high as expected, suggesting that alternative compensatory mechanisms are involved. Our work is centered in the identification of mechanisms responsible to the resistant to therapy anti-PLK1 that could not only improve patient selection and treatment efficacy but also open the door to new therapeutic combination strategies for the neoplasia showing the highest incidence in Spain.